Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Haifa Kathrin Al-Ali

Haifa Kathrin Al-Ali

Martin Luther University of Halle-Wittenberg
Preventing or reversing transfusion dependence to improve outcomes in myelofibrosis 1:27
Preventing or reversing transfusion dependence to improve outcomes in myelofibrosis
Haifa Kathrin Al-Ali • 6 Dec 2025
Fedratinib plus CC-486, an oral HMA, in accelerated-phase myelofibrosis: the FAMy trial 2:02
Fedratinib plus CC-486, an oral HMA, in accelerated-phase myelofibrosis: the FAMy trial
Haifa Kathrin Al-Ali • 6 Dec 2025
Novel approaches to upfront management of myelofibrosis 14:17
Novel approaches to upfront management of myelofibrosis
Donal McLornan et al. • 27 Jun 2025
Unmet needs in polycythemia vera: improving symptoms & qualify of life 2:57
Unmet needs in polycythemia vera: improving symptoms & qualify of life
Haifa Kathrin Al-Ali • 11 Jun 2023
Pelabresib in myelofibrosis: the MANIFEST trials 1:34
Pelabresib in myelofibrosis: the MANIFEST trials
Haifa Kathrin Al-Ali • 11 Jun 2023
Phase I/II study of a novel BET inhibitor, BMS-986158, alone & with ruxolitinib or fedratinib in MF 2:04
Phase I/II study of a novel BET inhibitor, BMS-986158, alone & with ruxolitinib or fedratinib in MF
Haifa Kathrin Al-Ali • 11 Jun 2023
KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy 5:24
KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy
Haifa Kathrin Al-Ali • 19 Jun 2020
The application of JAK inhibitors in the treatment of polycythemia vera and myelofibrosis 1:14
The application of JAK inhibitors in the treatment of polycythemia vera and myelofibrosis
Haifa Kathrin Al-Ali • 9 Jun 2016
The current research on momelotinib for myelofibrosis 2:07
The current research on momelotinib for myelofibrosis
Haifa Kathrin Al-Ali • 9 Jun 2016
Current research into JAK inhibitors – specifially ruxolitinib, pacritinib, and momelotinib 1:58
Current research into JAK inhibitors – specifially ruxolitinib, pacritinib, and momelotinib
Haifa Kathrin Al-Ali • 9 Jun 2016
What is the unmet medical need of patients with PV and ET? 2:47
What is the unmet medical need of patients with PV and ET?
Haifa Kathrin Al-Ali • 9 Jun 2016
How to manage myelofibrosis patients on momelotinib who develop peripheral neuropathy 0:50
How to manage myelofibrosis patients on momelotinib who develop peripheral neuropathy
Haifa Kathrin Al-Ali • 10 Jun 2016
Safety of treating myelofibrosis with ruxolitinib – results from JUMP trial 0:46
Safety of treating myelofibrosis with ruxolitinib – results from JUMP trial
Haifa Kathrin Al-Ali • 1 Dec 2016
The content of VJHemOnc is intended for healthcare professionals